Al-Hassany, Linda
Boucherie, Deirdre M.
Creeney, Hannah
van Drie, Ruben W. A.
Farham, Fatemeh
Favaretto, Silvia
Gollion, Cédric
Grangeon, Lou
Lyons, Hannah
Marschollek, Karol
Onan, Dilara
Pensato, Umberto
Stanyer, Emily
Waliszewska-Prosół, Marta
Wiels, Wietse
Chen, Hui Zhou
Amin, Faisal Mohammad
,
Funding for this research was provided by:
Teva
Novartis
Lundbeck
Lilly
FWO Vlaanderen Fundamental Research scholarship
Pfizer
Article History
Received: 31 December 2022
Accepted: 14 March 2023
First Online: 28 June 2023
Declarations
:
: Not applicable.
: Not applicable.
: Linda Al-Hassany, Deirdre M. Boucherie, Hannah Creeney, Ruben W.A.van Drie, Fatemeh Farham, Silvia Favaretto, Grangeon Lou, Hannah Lyons, Karol Marschollek, Dilara Onan, Umberto Pensato, Emily Stanyer, Marta Waliszewska-Prosół, Hui Zhou Chen declare no conflict of interest. Cédric Gollion reports speaker fees from Teva, Novartis, Lundbeck and Lilly. Wietse Wiels declares to have received an FWO Vlaanderen Fundamental Research scholarship. Faisal Mohammad Amin has received Honoraria or personal fees from Pfizer, Teva, Novartis, Lundbeck and Eli Lilly for lecturing or participating in advisory boards; is principal investigator for phase IV trials sponsored by Novartis and by Teva; serves as president of Danish Headache Society and board member of the European Headache Federation; serves as associate editor for Acta Neurol Scand, Front Neurol, Front Res Pain, and Headache Medicine; serves as junior associate editor for Cephalalgia and Cephalalgia Reports; member of the editorial board of J Headache Pain.